NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$1.1b

Last Updated

2021/05/07 22:35 UTC

Data Sources

Company Financials

Executive Summary

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Germany, and internationally. More Details

Rewards

PE ratio (35.8x) is below the Medical Equipment industry average (57.8x)

Risk Analysis

No risks detected for ATRI from our risk checks.


Snowflake Analysis

Flawless balance sheet second-rate dividend payer.


Similar Companies

Share Price & News

How has Atrion's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ATRI is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: ATRI's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-2.0%

ATRI

-2.5%

US Medical Equipment

-0.3%

US Market


1 Year Return

-7.8%

ATRI

33.9%

US Medical Equipment

50.2%

US Market

Return vs Industry: ATRI underperformed the US Medical Equipment industry which returned 33.8% over the past year.

Return vs Market: ATRI underperformed the US Market which returned 51.8% over the past year.


Shareholder returns

ATRIIndustryMarket
7 Day-2.0%-2.5%-0.3%
30 Day-2.5%4.2%2.2%
90 Day-10.3%1.8%3.8%
1 Year-6.8%-7.8%34.9%33.9%52.7%50.2%
3 Year8.1%5.2%73.1%69.0%63.4%53.1%
5 Year62.6%55.7%154.8%136.3%129.6%104.0%

Long-Term Price Volatility Vs. Market

How volatile is Atrion's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Atrion undervalued compared to its fair value and its price relative to the market?

35.79x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: ATRI ($625.97) is trading above our estimate of fair value ($211.97)

Significantly Below Fair Value: ATRI is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ATRI is good value based on its PE Ratio (35.8x) compared to the US Medical Equipment industry average (57.8x).

PE vs Market: ATRI is poor value based on its PE Ratio (35.8x) compared to the US market (20.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ATRI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATRI's PB Ratio (4.8x) is in line with the US Medical Equipment industry average.


Future Growth

How is Atrion forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

19.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Atrion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Atrion performed over the past 5 years?

4.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATRI has high quality earnings.

Growing Profit Margin: ATRI's current net profit margins (21.8%) are lower than last year (23.7%).


Past Earnings Growth Analysis

Earnings Trend: ATRI's earnings have grown by 4.4% per year over the past 5 years.

Accelerating Growth: ATRI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ATRI had negative earnings growth (-12.6%) over the past year, making it difficult to compare to the Medical Equipment industry average (10.5%).


Return on Equity

High ROE: ATRI's Return on Equity (13.4%) is considered low.


Financial Health

How is Atrion's financial position?


Financial Position Analysis

Short Term Liabilities: ATRI's short term assets ($112.3M) exceed its short term liabilities ($13.6M).

Long Term Liabilities: ATRI's short term assets ($112.3M) exceed its long term liabilities ($12.8M).


Debt to Equity History and Analysis

Debt Level: ATRI is debt free.

Reducing Debt: ATRI has not had any debt for past 5 years.

Debt Coverage: ATRI has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ATRI has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Atrion current dividend yield, its reliability and sustainability?

1.12%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: ATRI's dividend (1.12%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.24%).

High Dividend: ATRI's dividend (1.12%) is low compared to the top 25% of dividend payers in the US market (3.42%).


Stability and Growth of Payments

Stable Dividend: ATRI's dividends per share have been stable in the past 10 years.

Growing Dividend: ATRI's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (37.7%), ATRI's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

28.3yrs

Average board tenure


CEO

David Battat (50 yo)

10yrs

Tenure

US$2,065,635

Compensation

Mr. David A. Battat has been the Chief Executive Officer of ATRION Corp. since May 26, 2011 and has been its President since May 2011. Mr. Battat has been the President of Halkey-Roberts Corporation, a sub...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD2.07M) is about average for companies of similar size in the US market ($USD2.34M).

Compensation vs Earnings: David's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Board Members

Experienced Board: ATRI's board of directors are seasoned and experienced ( 28.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Atrion Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Atrion Corporation
  • Ticker: ATRI
  • Exchange: NasdaqGS
  • Founded: 1944
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$1.119b
  • Shares outstanding: 1.83m
  • Website: https://www.atrioncorp.com

Number of Employees


Location

  • Atrion Corporation
  • One Allentown Parkway
  • Allen
  • Texas
  • 75002-4211
  • United States

Listings


Biography

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Germany, and internat...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/07 22:35
End of Day Share Price2021/05/07 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.